X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (698) 698
humans (646) 646
esomeprazole (549) 549
pharmacology & pharmacy (548) 548
male (410) 410
proton pump inhibitors (405) 405
omeprazole (396) 396
female (363) 363
adult (306) 306
gastroenterology & hepatology (289) 289
middle aged (284) 284
lansoprazole (219) 219
gastroesophageal reflux - drug therapy (199) 199
treatment outcome (188) 188
aged (177) 177
esomeprazole - administration & dosage (165) 165
proton pump inhibitors - therapeutic use (163) 163
rabeprazole (156) 156
esomeprazole - therapeutic use (155) 155
pharmacokinetics (151) 151
gastroesophageal-reflux disease (146) 146
anti-ulcer agents - therapeutic use (126) 126
pantoprazole (125) 125
medicine & public health (121) 121
gastroesophageal reflux (119) 119
anti-ulcer agents - administration & dosage (117) 117
esomeprazole - pharmacology (114) 114
proton pump inhibitors - pharmacology (110) 110
young adult (108) 108
adolescent (106) 106
pharmacology/toxicology (106) 106
proton pump inhibitors - administration & dosage (105) 105
proton pump inhibitor (101) 101
esomeprazole - adverse effects (97) 97
therapy (96) 96
double-blind (93) 93
hydrogen-ion concentration (93) 93
internal medicine (93) 93
cross-over studies (91) 91
drug interactions (89) 89
dose-response relationship, drug (87) 87
double-blind method (87) 87
proton pump inhibitors - adverse effects (87) 87
drug therapy, combination (83) 83
anti-ulcer agents - pharmacology (81) 81
management (81) 81
erosive esophagitis (80) 80
drug therapy (75) 75
omeprazole - therapeutic use (75) 75
efficacy (74) 74
helicobacter infections - drug therapy (74) 74
clinical trials (70) 70
gastroesophageal reflux disease (69) 69
animals (68) 68
helicobacter pylori (67) 67
symptoms (67) 67
2-pyridinylmethylsulfinylbenzimidazoles (66) 66
gastric acid - secretion (66) 66
aged, 80 and over (64) 64
pharmacotherapy (63) 63
esomeprazole - pharmacokinetics (62) 62
esophagitis (62) 62
pharmacology (62) 62
administration, oral (61) 61
prospective studies (59) 59
dosage and administration (58) 58
omeprazole - pharmacology (58) 58
time factors (58) 58
care and treatment (57) 57
esomeprazole 40 mg (57) 57
health aspects (57) 57
drug administration schedule (56) 56
anti-ulcer agents - pharmacokinetics (54) 54
anti-ulcer agents - adverse effects (53) 53
research (52) 52
area under curve (51) 51
drugs (51) 51
intragastric ph (51) 51
risk factors (50) 50
risk (49) 49
analysis (48) 48
2-pyridinylmethylsulfinylbenzimidazoles - administration & dosage (47) 47
omeprazole - analogs & derivatives (47) 47
gerd (46) 46
proton pump inhibitors - pharmacokinetics (46) 46
quality-of-life (46) 46
disease (45) 45
heartburn (45) 45
proton-pump inhibitors (44) 44
helicobacter-pylori infection (43) 43
omeprazole - administration & dosage (43) 43
metaanalysis (42) 42
omeprazole - pharmacokinetics (42) 42
randomized controlled-trial (42) 42
toxicology (42) 42
helicobacter pylori - drug effects (41) 41
ranitidine (41) 41
aspirin (40) 40
esophagitis, peptic - drug therapy (40) 40
gastric acidity determination (40) 40
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (961) 961
French (6) 6
Chinese (3) 3
Spanish (3) 3
Russian (2) 2
Dutch (1) 1
Hungarian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Investigational New Drugs, ISSN 0167-6997, 4/2018, Volume 36, Issue 2, pp. 248 - 258
Aim Two studies investigated the effect of gastric acid reducing agents and strong inducers/inhibitors of CYP3A4 on the pharmacokinetics of alisertib, an... 
Aurora A kinase | Medicine & Public Health | Alisertib | Induction | Oncology | Drug-drug interactions | Inhibition | Pharmacology/Toxicology | CYP3A4 | SELECTIVE AURORA | ADVANCED SOLID TUMORS | SAFETY | PHASE-II | PHARMACODYNAMICS | ONCOLOGY | MLN8237 | PHARMACOLOGY & PHARMACY | CARCINOMA | Drugs, Investigational - pharmacology | Area Under Curve | Pyrimidines - blood | Humans | Drugs, Investigational - pharmacokinetics | Drugs, Investigational - therapeutic use | Esomeprazole - pharmacology | Male | Aurora Kinase A - antagonists & inhibitors | Itraconazole - pharmacology | Esomeprazole - therapeutic use | Dose-Response Relationship, Drug | Female | Rifampin - therapeutic use | Azepines - blood | Pyrimidines - pharmacology | Azepines - therapeutic use | Azepines - pharmacology | Itraconazole - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - pharmacokinetics | Azepines - pharmacokinetics | Protein Kinase Inhibitors - pharmacology | Rifampin - pharmacology | Complications and side effects | Dosage and administration | Research | Drug therapy | Rifampin | Cancer | Itraconazole | Reducing agents | Pharmacology | Variance analysis | Patients | Omeprazole | Confidence intervals | Studies | Inhibitors | Metabolites | Acids | Pharmacokinetics | Gastric juice | Inducers | Index Medicus | Phase I Studies
Journal Article
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 11/2004, Volume 96, Issue 22, pp. 1702 - 1713
Journal Article
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 05/2016, Volume 43, Issue 10, pp. 1048 - 1059
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 11/2013, Volume 38, Issue 9, pp. 1129 - 1137
Journal Article
Journal Article
Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 06/2007, Volume 321, Issue 3, pp. 866 - 874
Journal Article